[NMusers] Register Today - 17th Advanced Population PK/PD Data Analysis in Germany

From: Andre Keller <Andre.Keller_at_certara.com>
Date: Tue, 10 Feb 2015 15:30:10 +0000

Dear Members,

You are invited to join Dr. Daniel Weiner for the 17th Advanced Level Works=
hop on Pharmacokinetic-Pharmacodynamic Data Analysis in Munich, Germany. Se=
cure your place by registering early and receive a 20% discount! (expires 1=
8 March 2015)

Interested in a custom on-site training course? Follow the link to view the=
 benefits of on-site training and to request a proposal: http://info.certar=

17th Advanced Level Workshop on Pharmacokinetic - Pharmacodynamic Data Anal=

May 18-21, 2015

Munich, Germany

Register Here: https://www.certara.com/training/classes/73

Learn to apply advanced approaches for conducting PK/PD analysis. This cour=
se aims to give the course participants confidence and encouragement to hav=
e a go at PK/PD and to practice PK/PD data analysis on real life case studi=
es from discovery, preclinical and development. The program is comprised o=
f lectures and group exercises with discussion, combined with hands-on PK/P=
D data analysis sessions.

Who should attend?

Scientists with at least five years of experience in PK/PD modeling. Qualif=
ied graduate students.

Topics include:

Dose-response-time analysis, advanced principles of turnover modeling inclu=
ding modeling tolerance and rebound, approaches to TMDD modeling, approache=
s to optimizing sampling collection times, modeling PD effects for combinat=
ion drug treatments, pattern recognition, and translational aspects of PK/P=
D modeling.

Course includes:

Complimentary copy of Pharmacokinetic & Pharmacodynamic Data Analysis [with=
 CDROM] by Johan Gabrielsson and Dan Weiner.

Lectures, group exercises with discussion, and hands-on PK/PD data analysis=
 including population PK/PD modeling using Phoenix WinNonlin and NLME. Disc=
ussions and exercises will enable participants to master state-of-the-art a=
pproaches to real-life problems.

Daniel Weiner Ph.D.

Dr. Weiner has extensive drug development experience and has served as an e=
xpert consultant to the U.S. Food and Drug Administration (FDA) on pharmaco=
kinetic modeling and bioequivalence assessment. Prior to his previous tenur=
e with Pharsight as a Senior Vice President, Dr. Weiner held several manage=
ment positions including Head, Biostatistics, Merrell Dow Pharmaceuticals; =
Vice President, Statistical Consultants, Inc.; Vice President, Syntex Devel=
opment Research; Senior Vice President and Principal Scientist, Quintiles, =
and most recently, Senior Vice President and Global Head of Clinical Develo=
pment at IVAX Research.

Kind regards,

Andre Keller
5520 Dillard Dr., Suite 260
Cary, NC 27518
Tel +1-919-852-4611
www.certara.com<http://www.certara.com/> NOTICE: The information co=
ntained in this electronic mail message is intended only for the personal a=
nd confidential use of the designated recipient(s) named above. This m=
essage may be an attorney-client communication, may be protected by th=
e work product doctrine, and may be subject to a protective order. As such,=
 this message is privileged and confidential. If the reader of this me=
ssage is not the intended recipient or an agent responsible for delivering =
it to the intended recipient, you are hereby notified that you have re=
ceived this message in error and that any review, dissemination, distr=
ibution, or copying of this message is strictly prohibited. If you have rec=
eived this communication in error, please notify us immediately by tel=
ephone and e-mail and destroy any and all copies of this message in yo=
ur possession (whether hard copies or electronically stored copies). Thank =
you. buSp9xeMeKEbrUze

Received on Tue Feb 10 2015 - 10:30:10 EST

This archive was generated by hypermail 2.3.0 : Fri Sep 27 2019 - 16:42:59 EDT